People: Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

3.96AUD
29 Jul 2015
Change (% chg)

$-0.01 (-0.25%)
Prev Close
$3.97
Open
$4.02
Day's High
$4.02
Day's Low
$3.94
Volume
240,189
Avg. Vol
357,716
52-wk High
$5.88
52-wk Low
$3.17

Search Stocks

Weiner, Ben-Zion 

Dr. Ben-Zion Weiner, ph.D., has been Non-Executive Independent Director of Mesoblast Ltd since May 9, 2012. Ben-Zion Weiner was head of global research and development at Teva Pharmaceutical Industries Ltd for over three decades, including as Chief R&D Officer and a member of the Teva Executive Committee. He directly oversaw all pharmaceutical R&D and innovative branded product pipeline development. Dr Weiner has been responsible for the development of hundreds of generic products for the United States, European and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva’s innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis. He retired from Teva at the end of 2012. Dr Weiner is no longer affiliated with Teva and continues to serve on the Mesoblast Board as an independent nonexecutive Director. He was Director of Gefen Biomed Investments Ltd (2010 to 2013) and Board Member of XTL Biopharmaceuticals Limited (2012 to 2013).

Basic Compensation

Total Annual Compensation, AUD 134,667
Restricted Stock Awards, AUD --
Long-Term Incentive Plans, AUD --
All Other, AUD --
Fiscal Year Total, AUD 134,667

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Brian Jamieson

343,322

Silviu Itescu

1,817,780

Paul Hodgkinson

--

Charlie Harrison

--

William Burns

44,145

Donal O'Dwyer

174,436
As Of  29 Jun 2014
Search Stocks